Teresa Lambe

University of Oxford - The Jenner Institute

Old Road Campus Research Building Roosevelt Drive

Oxford, Oxfordshire OX3 7DQ

United Kingdom

SCHOLARLY PAPERS

9

DOWNLOADS
Rank 172

SSRN RANKINGS

Top 172

in Total Papers Downloads

97,348

SSRN CITATIONS

5

CROSSREF CITATIONS

3

Scholarly Papers (9)

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Number of pages: 37 Posted: 01 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Siena - Institute of Global Health, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, Federal University of Sao Paulo, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of the Witwatersrand, Soweto Clinical Trials Centre, Soweto Clinical Trials Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, Setshaba Research Centre, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Wits Reproductive Health & HIV Institute (WRHI), University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Oxford Vaccine Group, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University Hospitals Bristol and Weston NHS Foundation Trust, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, Liverpool School of Tropical Medicine - Department of Clinical Sciences, AstraZeneca Pharmaceuticals, University of the Witwatersrand - South African Medical Research Council, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - South African Medical Research Council, University of the Witwatersrand - South African Medical Research Council, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Oxford - Centre for Vaccinology and Tropical Medicine, AstraZeneca Pharmaceuticals, Braziland Hospital São Rafael - Escola Bahiana de Medicina e Saúde Pública, Universidade Federal do Rio Grande do Norte (UFRN), University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - Perinatal HIV Research Unit, Setshaba Research Centre, University of Oxford - Oxford Vaccine Group, Hospital Quinta D'OR, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Hospital Universitário de Santa Maria, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Universidade Federal do Rio Grande do Sul, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, University of Cambridge - Department of Medicine, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine and Independent
Downloads 51,876 (30)
Citation 3

Abstract:

Loading...

2.

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

Number of pages: 45 Posted: 25 Jun 2021
University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Public Health England Colindale, Government of the United Kingdom - Public Health Scotland, Liverpool School of Tropical Medicine - Department of Clinical Sciences, Liverpool School of Tropical Medicine - Department of Clinical Sciences, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University Hospitals Birmingham NHS Foundation Trust, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, University of Oxford - The Jenner Institute, Government of the United Kingdom - North Bristol NHS Trust, NIHR UCLH Clinical Research Facility, Public Health England - Immunisation, Hepatitis, and Blood Safety Department, University of Southampton - University Hospital Southampton NHS Foundation Trust, Nottingham University Hospitals NHS Trust, Imperial College London - National Heart & Lung Institute, University of Nottingham - Division of Epidemiology and Public Health, University of Oxford - Centre for Vaccinology and Tropical Medicine and Independent
Downloads 25,020 (130)
Citation 4

Abstract:

Loading...

3.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Number of pages: 40 Posted: 04 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Oxford - Big Data Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - The Jenner Institute, Public Health England - National Infection Service, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, UK Biocentre, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - Oxford Vaccine Group, University Hospitals Bristol and Weston NHS Foundation Trust, University of Oxford - The Jenner Institute, University of Oxford - Jenner Institute, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, Queen Elizabeth University Hospital, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Cambridge, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent and Independent
Downloads 10,084 (704)
Citation 25

Abstract:

Loading...

4.

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Number of pages: 35 Posted: 28 Jun 2021
University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute and Independent
Downloads 8,375 (966)
Citation 10

Abstract:

Loading...

5.

Randomized Immunogenicity and Safety Study of Heterologous Versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses Of Coronavac COVID-19 Vaccine

Number of pages: 32 Posted: 30 Dec 2021
University of Siena - Institute of Global Health, Federal University of Sao Paulo, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine and affiliation not provided to SSRN
Downloads 949 (33,762)

Abstract:

Loading...

Randomized, Immunogenicity, Safety, study, heterologous, homologous, COVID-19, booster, vaccination, two dose, three dose, third, second, Coronavac, Sinovac, SARS-CoV-2, schedule, coronavirus, pandemic, Oxford, Brazil, Ministry of Health, protection

6.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

Number of pages: 39 Posted: 19 Apr 2021
University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, NIHR Imperial Clinical Research Facility, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University College London - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Oxford Vaccine Group, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, NIHR Guy's and St Thomas' Biomedical Research Centre, Imperial College London - Department of Infectious Disease, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Oxford University Hospitals NHS Foundation Trust, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Department of Paediatrics, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Imperial College London - Department of Infectious Disease, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Imperial College London - Department of Medicine, Guy's and St Thomas' NHS Foundation Trust - Harrison Wing, University of Oxford - The Jenner Institute and Independent
Downloads 606 (61,568)
Citation 2

Abstract:

Loading...

7.

COVID Symptoms, Seroprevalence, and Mortality During the First Wave of SARS-CoV-2 in Canada

Number of pages: 17 Posted: 25 Jan 2021
University of Toronto - Centre for Global Health Research, Centre for Global Health Research, Unity Health Toronto, St. Joseph’s Health Centre, Unity Health, Sinai Health System TorontoUniversity of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto, Toronto, Canada - Department of Medicine, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto - University Health Network, University of Ottawa - Department of Biochemistry, Microbiology and Immunology, Angus Reid Institute, Angus Reid Institute, Angus Reid Institute, Angus Reid Institute, University of Oxford - The Jenner Institute, University of Toronto - Mount Sinai Hospital, Toronto, Sinai Health TorontoUniversity of Toronto - Mount Sinai Hospital, Toronto, University of Toronto - Mount Sinai Hospital, Toronto, University of Toronto - Mount Sinai Hospital, Toronto, St. Joseph’s Health Centre, Unity Health, Sinai Health Toronto, Mount Sinai School of Medicine, University of Toronto - Centre for Global Health Research, Centre for Global Health Research, Unity Health Toronto, University of Toronto - Centre for Global Health Research, Centre for Global Health Research, Unity Health Toronto, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, University of Toronto - Centre for Global Health Research, Sinai Health Toronto, Angus Reid Institute, University of Toronto - Mount Sinai Hospital, Toronto, University of Ottawa, Unity Health Toronto and University of Toronto - St. Michael's Hospital
Downloads 261 (160,820)

Abstract:

Loading...

8.

Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility

Number of pages: 30 Posted: 05 Jan 2021
Imperial College London - Section of Infectious Diseases and Immunity, Department of Infectious Disease, Imperial College London, Department of Infectious Disease, Imperial College London, Department of Infectious Disease, Imperial College London, Department of Infection and Immunity, Imperial College Healthcare NHS Trust, Department of Infectious Disease, Imperial College London, Department of Infectious Disease, Imperial College London, Worldwide Influenza Centre, Francis Crick Institute, Worldwide Influenza Centre, Francis Crick Institute, The Wellington Hospital, The Wellington Hospital, The Wellington Hospital, Blood Borne Virus Unit, National Infection Service, Colindale Public Health England, Blood Borne Virus Unit, National Infection Service, Colindale Public Health England, Department of Infectious Disease, Imperial College London, Department of Infectious Disease, Imperial College London, Department of Infectious Disease, Imperial College London, Department of Infectious Disease, Imperial College London, Department of Infectious Disease, Imperial College London, Chromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, Structural Biology Science Technology Platform, Francis Crick Institute, King's College London, Department of Virology, King’s College Hospital, Imperial College London - Department of Infectious Disease, Department of Infectious Disease, Imperial College London, Department of Infectious Disease, Imperial College London, Imperial College London - Department of Epidemiology and Biostatistics, Jenner Institute, University of Oxford, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Department of Infection and Immunity, Imperial College Healthcare NHS Trust, University of Edinburgh - Roslin Institute, Imperial College London - National Heart and Lung Institute, University of Liverpool - Health Protection Research Unit in Emerging and Zoonotic Infections, Independent, Department of Infectious Disease, Imperial College London and Imperial College London - Department of Infectious Disease
Downloads 137 (284,124)
Citation 2

Abstract:

Loading...

9.

Fatal COVID-19 Outcomes are Associated with an Antibody Response Targeting Epitopes Shared with Endemic Coronaviruses

Number of pages: 32 Posted: 02 Jun 2021
University of Oxford, University of Oxford, University of Oxford, St. George’s University of London - Institute of Infection & Immunity, University of Oxford, University of Oxford, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford, St. George's University - Intensive Care Medicine, University of Cambridge, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, University of Oxford, Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College, London, University of Oxford, University of Oxford, University of Oxford, St. George's University - General Intensive Care, University of Oxford, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Nuffield Department of Medicine, St George's, University of London, University of Oxford - Wellcome Trust Centre for Human Genetics, University of Oxford, University of Oxford, University of Oxford - Wellcome Centre for Human Genetics, Oxford University Hospitals NHS Foundation TrustUniversity of Oxford - Nuffield Department of Clinical Neurosciences, University of Oxford, University of Oxford - Wellcome Centre for Human Genetics, University of Kent - Viral Pseudotype Unit, Meso-­?Scale Diagnostics, University of Oxford - Wellcome Centre for Human Genetics, Guy's and St Thomas' NHS Foundation Trust - Intensive Care Medicine, Independent, Independent, University of Oxford - Nuffield Department of Medicine, University of Oxford - The Jenner Institute, University of Edinburgh - Roslin Institute, University of Liverpool - Health Protection Research Unit in Emerging and Zoonotic Infections, Imperial College London - National Heart and Lung Institute, Independent, Tel-Aviv University, Leidos Inc., University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford, affiliation not provided to SSRN, Oxford University Hospitals NHS Foundation Trust, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Department of Zoology, University of Oxford - Peter Medawar Building for Pathogen Research, St. George’s University of London - Institute of Infection & Immunity, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Department of Zoology and University of Oxford - Peter Medawar Building for Pathogen Research
Downloads 40 (561,449)
Citation 2

Abstract:

Loading...